Turns out there are quite a few people who would like to see the end of Tom Cigarran's two-decade involvement with surgery center operator AmSurg.
At AmSurg's annual meeting of shareholders last week, investors overwhelmingly voted in favor of various par-for-the-course proposals as well as the re-election to three-year terms of directors Cynthia Miller and John Popp. Not so with Cigarran, chairman of AmSurg from 1992 to 2009 and its CEO for four years during the '90s. He received just 58.5 percent of the possible votes.
Cantor Fitzgerald analyst Joe France says investors shouldn't look to AmSurg for price appreciation in the near future. Initiating coverage with a 'hold' rating and a price target of $26, France says "the extent of the market's recovery is unclear" and that CEO Chris Holden and his team have their hands full integrating National Surgical Care. Shares of AmSurg (Ticker: AMSG) closed Monday trading just above $26 and are flat for the year.
Cantor Fitzgerald analyst Joe France has launched coverage of a number of local health care names most notably hospital chain Community Health Systems, LifePoint and Vanguard. He says investors should be the latter two — Vanguard because it could be one of the industry's fastest growers and LifePoint because of its push into larger markets. When it comes to CHS, France says management's focus on integrating new acquisitions make it more of a long-term play.
Shares of all three companies are up more than 2 percent in Friday morning trading.
Let's call it the "Go big or go home" clause.
The compensation committee of AmSurg has added a somewhat peculiar sweetener to the 2012 cash bonus plan for the surgery center chain's executives. In addition to the usual potential payouts — which are governed by criteria such as overall earnings and surgery center profits — CEO Chris Holden and his lieutenants stand to get extra cash "in the event the Company completes an acquisition transaction that is not subject to the bonus provisions described above, such as the acquisition of another company."
For Holden, striking a deal like his $143 million purchase last year of a Dallas-based company could fatten his wallet by up to $168,000, based on his 2011 salary. AmSurg's five other top execs would be in line to collect a total of more than $200,000.
Two executive vice presidents at surgery center chain AmSurg have been busy this month cashing in on thousands of stock options about to expire. CFO Claire Gulmi has booked a profit of more than $280,000 since Nov. 3 by first exercising 30,500 options and then selling the resulting shares. (Check the filings here and here.) Chief Development Officer David Manning followed a similar route, converting 12,000 options and selling the shares they turned into. (His filings are here and here.) Shares of AmSurg (Ticker: AMSG) have climbed about 20 percent in 2011.
POSTDATA: WARRANTY DEEDS
- TIPTON, JOHN H JR; TIPTON, FRANCES ADAMS
- HARRIS, JUDY C
- BIRDWELL, MARIAN ESTELLE TRUSTEE; BIRDWELL CHARLES EDWARD AND MARIAN ESTELLE BIRDWELL REVOCABLE TRUST; BIRDWELL MARIAN ESTELLE REVOCABLE TRUST; CHARLES EDWARD BIRDWELL AND MARIAN ESTELLE BIRDWELL REVOCABLE TRUST; MARIAN ESTELLE BIRDWELL REVOCABLE TRUST
- SIMPKINS, W L JR; SIMPKINS, NANCY H